Details of the Drug

General Information of Drug (ID: DMBT2D2)

Drug Name
AZD8233
Synonyms ION449
Indication
Disease Entry ICD 11 Status REF
Cardiovascular disease BA00-BE2Z Phase 2 [1]
Hypercholesterolaemia 5C80.0 Phase 2 [1]
Drug Type
Antisense oligonucleotide
Cross-matching ID
TTD ID
D81WHA
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PCSK9 messenger RNA (PCSK9 mRNA) TTNIZ2B PCSK9_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Cardiovascular disease
ICD Disease Classification BA00-BE2Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
PCSK9 messenger RNA (PCSK9 mRNA) DTT PCSK9 4.82E-02 -0.07 -0.3
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04964557) A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants With Hyperlipidaemia. U.S.National Institutes of Health.
2 AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval. Br J Clin Pharmacol. 2022 Nov;88(11):4839-4844.